Evidence map›Paper›PMID 40066035›Full record

ReviewHeliyon2025

Pharmaceutical applications of halophilic enzymes.

Maryam Yavari-Bafghi, Mohammad Ali Amoozegar

Abstract readReview
In one paragraph

Review in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Complete genome sequence ofMicrobiology resource announcements · 2026
    Article
  6. Recent Advances in Understanding Bio-Compounds from Haloarchaea.Journal of microbiology and biotechnology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Journal of bacteriology · 2025
    Review
  12. Lipase production fromFrontiers in microbiology · 2025
    Article
  13. A halophilic metalloprotease fromFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Maryam Yavari-BafghiDepartment of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
Mohammad Ali AmoozegarDepartment of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Halophiles produce extraordinarily stable enzymes under conditions where conventional enzymes cease to function, denature, and precipitate. Halophilic enzymes have adapted to function optimally at high salt concentrations besides tolerance of organic solvents and thermal stability. These special features offer potential advantages of cost-effectiveness and improved treatment outcomes that make them valuable for pharmaceutical purposes including the synthesis, design, and discovery of new drugs. The article highlights the unique characteristics and adaptation strategies of halophiles towards salinity. It provides an overview of halophilic enzymes' pharmaceutical applications and examines different challenges, opportunities, and recent advances in applying these enzymes in this field.

Indexed as

HalophilesHalophilic enzymesPharmaceutical applications

Identifiers

PMID40066035
PMCPMC11891729

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.